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Why was the cohort set up?
Childhood vaccination programmes have significantly
reduced childhood morbidity and mortality.1 Since 2000,
there has been an unprecedented expansion of routine
childhood vaccination and increased access to new vac-
cines in developing countries.2,3 Vaccines protect the indi-
vidual recipient (direct protection) but they may also
protect the whole population (indirect protection) if they
interrupt the chain of transmission of the target disease.4,5
Good quality population- and-individual level epidemiolo-
gical data are needed to estimate direct and indirect effects
and inform vaccination policy at the national level. To as-
sure society that a vaccine programme is safe, it is also ne-
cessary to monitor for adverse events following
immunization (AEFI).
During the introduction and expansion of access to new
vaccines in low- and middle-income countries (LMICs),
relatively few investments are allocated to evaluation of
the impact and cost effectiveness of vaccination
programmes, which is required to achieve long-term sus-
tainability of new vaccine programmes in LMICs. The cap-
acity for these kinds of impact assessments has lagged
significantly behind the introduction of new vaccines. As a
result, only a very small number of low-income countries
have the platforms required to assess vaccine impact, ef-
fectiveness and safety. Some countries have national or
subnational platforms for monitoring vaccine coverage,
e.g. in Health and Demographic Surveillance Systems, peri-
odic multi-indicator cluster surveys and Demographic and
Health Surveys (DHS). Although these can be linked to
mortality surveillance in HDSS sites to determine the popu-
lation effects of vaccines, data quality and interpretation
are limited.
The Kenya Medical Research Institute-Wellcome Trust
Research Programme (KWTRP) in Kilifi set up the
Haemophilus influenzae type b (Hib) conjugate vaccine ef-
fectiveness study in 2000. It was further expanded in 2008
with addition of the real-time vaccine monitoring
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component, in anticipation of the introduction of pneumo-
coccal conjugate vaccine (PCV) in Kenya. The objective of
the Kilifi Vaccine Monitoring Study (KiVMS), a long-term
continuous cohort study, is to investigate effectiveness, im-
pact, coverage, safety and indirect vaccine effects by re-
cruiting birth cohorts as well as cohorts of older children
and adults where applicable, within a well-characterized
population and area. In addition, KiVMS is used to explore
the determinants of vaccine coverage and acceptability in
the population. Built on the platform of a Health and
Demographic Surveillance System (HDSS), KiVMS inte-
grates morbidity surveillance systems at the County
Department of Health (CDOH), Kilifi, and a population-
based, computerized information system for collecting vac-
cination data. Therefore it has the following essential attri-
butes: continuously updated demographic data from the
population of interest (e.g. births, deaths and migration);
and complete and accurate vaccination records for the
catchment population. Vaccine information systems are
rare in tropical Africa.
Here we describe the study population and provide an
overview of the data sources and data management
processes.
Who is in the cohort?
Setting
Kenya is divided administratively into 47 counties.6,7 Kilifi
County, on the Indian Ocean Coast, is one of the poorest6
and is typical of a rural equatorial Africa setting. KiVMS is
based in Kilifi, with the area covered by the Kilifi HDSS
(KHDSS) as shown in Figure 1. The KHDSS has a popula-
tion of 280 000 covering an area of 891 km2.8
Inclusion
The primary target of this study is the population of chil-
dren aged < 5 years, resident in the study area. The
KHDSS has a birth cohort of  8000 per annum. In add-
ition, all childhood immigrants are recruited, along with
their families, into the KiVMS during re-enumeration
rounds. From January 2011 to 31 December 2014, there
were 33 962 children in the birth cohort database.
Community engagement and governance
KiVMS was conceived at the outset as collaboration be-
tween the Ministry of Health and the KWTRP. A
Memorandum of Understanding between both parties
guides this collaboration. Its purpose is to support national
and regional policy making by providing informative local
data. In addition, this resource provides evidence to sup-
port the functions of the newly established Kenya National
Immunisation Technical Advisory Group (KENITAG).
Ethical approval
The KEMRI Scientific and Ethics Review Unit approved
this study and the activities carried out on the KHDSS
platform.
What has been measured?
Basic demographic data
Basic demographic data are obtained from the KHDSS
platform. In brief, these include global information system
(GIS) mapping of homestead location, household name
and head, individuals, residency status, births, deaths and
migration. The KHDSS is a longitudinal surveillance of the
population living in a well-defined geographical area
around Kilifi County Hospital (KCH), which has been
updated through household visits, monitoring vital events
and migration, since the year 2000.8
Ascertainment of vaccination
Using an electronic vaccine monitoring system established
at all 34 health facilities delivering vaccines and 53
affiliated outreach sites in the KHDSS (Figure 1), data
clerks record vaccine data (Table 1). Vaccine clinics are ei-
ther government26 or privately8 owned and located within
or just outside the KHDSS boundaries. Children presenting
to these are matched to their unique personal record in the
population register. If their details do not exist in the
KHDSS database, they are registered as new once matched
to the mother’s homestead and details. If they are not
matched to a household, they are registered with a tempor-
ary identification pending resolution of the associated data
query. Manual registers provide a source of back-up data
for verification like the vaccine cards retained by mothers/
caregivers, which are labelled with a unique identity num-
ber. Linkage of clinic and central server data is achieved
weekly; data captured at the clinics during daily operations
are uploaded to laptops brought on site by data super-
visors, and the latest version of the population register is
downloaded to data clerks’ laptops. The population regis-
ter is also updated with data of children newly registered at
the vaccine clinics and previously unknown to the KHDSS.
All of the data are delivered to the central data server at
the KWTRP. The synchronisation lag time is usually 1
week. The linkages between the constituent parts of the
KiVMS are outlined in Figure 2.
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Morbidity surveillance
All paediatric and adult admissions undergo detailed clin-
ical and laboratory evaluation(s) for vaccine-preventable
disease surveillance at the KCH, a 172-bed (and 20-cot) fa-
cility at the centre of the KHDSS area that provides pri-
mary care and serves as a first-level referral hospital.8 It is
equipped for basic haematological and biochemical tests
and advanced microbiological culture. It also offers basic
radio-diagnostic support.12 Records of births and maternal
Figure 1. Areas and facilities covered by the Kilifi Vaccine Monitoring Study.
Table 1. Data recorded in the Kilifi Vaccine Monitoring
System
Characteristics KiVMS database
Attributes of
the child
1. Child’s name
2. Date of birth
3. Unique personal identifier for child’s
vaccine card
4. Unique personal identifier for child’s mother
5. Mother and homestead data
6. Residence, and demographic details if
individual is not in the database
Attributes of
vaccine
clinic visit
1. Vaccine clinic visited
2. Type of visit-for vaccination or
anthropometry
3. Data entry clerk identifier
4. Update of all vaccines recorded in vaccine card
but not seen in registry
Attributes of
vaccine
1. Date of vaccination
2. Vaccine delivered/stock out
3. Refusals
4. Type of vaccine and dose given
5. Vaccine aliquot given (for multi-dose vials)
Attributes of
hospital visit
1. Date of admission
2. Duration of admission
3. Admission and discharge diagnosis
4. KHDSS residence status
Figure 2. Illustration of the linkages between the constituent parts of the
Kilifi Vaccine Monitoring System (KiVMS).
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deaths are also recorded from the maternity section in real
time. KiVMS is supported by a bespoke database and plat-
form that integrates electronic health records at KCH with
vaccination records and the KHDSS population register.
Individuals at admission or delivery are matched with the
population register, creating a permanent link between the
patient’s residence record and the hospital event.
Individuals are matched on five criteria: name, sex, date of
birth, residence and homestead characteristics.
Cross-sectional surveys
Surveys of intermediary markers of vaccine impact, such as
nasopharyngeal carriage of pneumococci or serological re-
sponses to vaccine-preventable diseases, are assessed
through recurrent standardized surveys by age-stratified
random sampling of the entire population. These have
been used to determine the interruption of transmission of
pneumococci9 and the population immunity to Hib vac-
cine.10 In addition, we propose to validate epidemiological
measures of vaccine coverage using these samples.
How often have they been followed up?
Vaccination data are recorded at every vaccine clinic visit.
Re-enumeration of births, deaths and migration events in
the KHDSS occurs three times a year.8 Nasopharyngeal
carriage studies are carried out annually and the sero-
logical surveys biannually.9 In addition, births are recorded
continuously as they occur or at first contact in the com-
munity during re-enumeration or at clinics during vaccin-
ation visits. Morbidity surveillance at the KCH is
continuous.
What has been found? Key findings and
publications
Vaccine impact using before-after studies
The introduction, in 2001, of Hib conjugate vaccine (as
pentavalent vaccine with diphtheria, tetanus, whole-cell
pertussis and hepatitis B antigens) was the precipitant for
the development of the KiVMS. Using population-linked
morbidity surveillance, we showed an 88% effectiveness of
the vaccination programme against invasive Hib disease in-
cidence among children aged less than 5 years, within 3
years of introducing the vaccine.11 Fifteen years on, and
without a booster dose, vaccine effectiveness is 93% and
sero-surveys confirm enduring population immunity.10
KiVMS currently supports the Pneumococcal Conjugate
Vaccine Impact Study (PCVIS), a before-after study of the
impact of the 10-valent pneumococcal conjugate vaccine
(PCV-10) introduced in January 2011. Linkages between
the vaccine registry and morbidity surveillance databases
permit an individual-based cohort analysis of the entire
population by connecting rates of invasive pneumococcal
disease (IPD) to vaccine status. Dividing the numbers of
IPD cases by the person-years of observation in different
exposure strata (unvaccinated, partially and fully vacci-
nated) provides estimates of the total and indirect effects of
PCV-10. The impact on the incidence of clinical and radio-
logically confirmed pneumonia and invasive pneumococcal
disease will be reported in 2016.
KiVMS was recently adapted to estimate the impact of
the newly introduced rotavirus vaccine. Between 2002 and
2004, incidence of hospitalizations with Group A rotavirus
gastroenteritis was 1431 [95% confidence intervals
(CI])1275-1600] per 10,000 person years of observation
(pyo) in infants.12 Ongoing surveillance shows these rates
declined appreciably over time before vaccine introduction
in July 2014. It is important to adjust for secular trends
like these in assessments of vaccine impact, especially if
this change is thought to be due to changes in associated
risk factors. Rotavirus vaccination impact data will be
available in 2017.
Epidemiological studies of transmission and sero-
prevalence
Following the introduction of PCV-10 with a catch-up
campaign in all children aged < 5 years in the KHDSS, an-
nual studies of nasopharyngeal carriage demonstrated a re-
duction of 64% (95% CI 49-74%) in the prevalence of
vaccine serotype pneumococci among children aged < 5
years. There was also a 66% (95% CI 38-82%) reduction
in carriage prevalence among unvaccinated older children
and adults, illustrating a profound and rapid indirect pro-
tection and predicting a decline in IPD across the whole
population.9
Assessments of vaccine coverage, timeliness and
equity
KiVMS provides a platform to validate administrative and
survey-based methods for assessing vaccine coverage.
Similarly to others,13 we found that compared with survey
data, administrative estimates exaggerate vaccine cover-
age.14 Within KHDSS, we have observed that seasonality
and family size are strong factors that determine cover-
age.14,15 KiVMS allows for review of patterns of coverage
over time to monitor programme performance by birth co-
hort and locations (Figure 3A, B); it gives insights into
equity of access by its sensitivity for identification of sub-
populations with low vaccination coverage (Figure 3C)
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Figure 3. Five-year pattern of coverage and time-to-vaccination for the third dose of the DPT (pentavalent) vaccine. (A) By birth cohort in the KiVMS
overall. (B) By birth cohort in all KiVMS study locations. (C) By birth cohort in one location, Roka, within the KiVMS study area.
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and can also be used to investigate vaccine failures and tar-
get interventions. Predictors of vaccine inequity and hesi-
tancy in at-risk groups such as recent migrants and young
mothers, and in geographical pockets of poor coverage,
can also be investigated.
Complex before and after studies
Before-after studies and case-control studies are susceptible
to similar biases. In routine practice, the population of chil-
dren who are not immunized may differ from the majority
with respect to background incidence or the extent to
which their disease outcome can be fully ascertained. An
accurate estimate of effectiveness for individual protection
(direct effect) can only be obtained by adjusting for con-
founding by ‘healthy’ vaccinees.16 It is important to iden-
tify these ascertainment biases and to control for them to
the extent possible, for example by estimating the protec-
tion from disease by receipt of an unrelated vaccine. The
schematic shown in Figure 4 highlights the various cohort
and incidence rate comparisons required to estimate the
overall vaccine impact as well as the direct and indirect
protection by a vaccine.
A further complexity arises from secular changes in dis-
ease risk factors. As vaccine ‘exposure’ is always associated
with time in a before-after study, any risk factor that also
varies with time may be a confounder. In tropical Africa,
the risk factors for vaccine-preventable diseases are com-
plex and may include malaria, malnutrition and HIV infec-
tion. Analyses of incidence ratios attributable to
vaccination in an interrupted time series analyses, for
example,17 can adjust for secular trends in major con-
founders but only if these data are available. By virtue of
its setting within a community and hospital-based research
station of over 25 years’ duration, the KiVMS has access to
data on many of these variables.18
Vaccine safety monitoring
KiVMS follows a relatively small annual birth cohort com-
pared with the national immunization programme, but it
has the capacity to accurately define temporal associations
between recent vaccination and deaths or serious life-
threatening events presenting to hospital. When the World
Health Organization (WHO) considered the introduction
of PCV10 as a two-dose vial without a preservative, they
were concerned about the theoretical risk of bacterial con-
tamination of an opened vial leading to AEFI after the se-
cond dose in the vial. We studied the problem for the first
2 years of introduction. The absence of any measurable
safety signal in vaccination site abscesses, sepsis or death
after immunization helped in the approval of PCV10 intro-
duction into other countries using the two-dose vial.19
Because the mortality burden attributable to many vac-
cine-preventable diseases is high in sub-Saharan Africa
(sSA), the issue of vaccine safety has not been the primary
focus of society. However, experience from developed
countries suggests that vaccines may be valued less highly
once the target disease has been brought under control,
and assurances of safety are essential for the sustainability
of the programme.
Figure 4. Comparisons required for estimating overall vaccine effectiveness, and direct and indirect vaccine effects.
6 International Journal of Epidemiology, 2016, Vol. 00, No. 00
 by guest on O
ctober 31, 2016
http://ije.oxfordjournals.org/
D
ow
nloaded from
 
In 2014, Kenya scaled up its maternal tetanus vaccin-
ation programme because earlier efforts and success had
brought the country within range of the global maternal
and neonatal tetanus elimination threshold, i.e. incidence
< than 1 case per 1000 live births.20 Unfortunately, a
group of religious leaders accused the government of plan-
ning to sterilize women by giving beta-human chorionic
gonadotropin (HCG)-containing tetanus vaccines,
and campaigned against this initiative.21 To support their
position, they argued that the expanded programme
was not justified because there were no more cases of neo-
natal tetanus in the country. However, data from
Kilifi clearly showed the impact of the immunization pro-
gramme and the need to build on the progress achieved
already.22
What are the main strengths and
weaknesses?
The evaluation of population impact and safety in the di-
verse epidemiological settings where vaccines are intro-
duced receives less attention compared with phase III trials
to demonstrate individual vaccine efficacy. Although
KiVMS has evolved to meet a specific need in Kenya, its
principal strength is its unique integration of a vaccine
registry and a morbidity surveillance system on top of the
largest HDSS in Africa. As a cohort study and integrated
surveillance platform, it facilitates population-level vaccine
impact assessments. The benefits of such a set-up have re-
cently been recognized by the INDEPTH network in its re-
cently proposed model: the Comprehensive Health and
Epidemiological Surveillance System (CHESS).23 It is a
very efficient study template for gathering data on vaccine
effectiveness and safety, which can be copied or deployed
across heterogeneous locations in the developing world. It
has provided evidence of direct and indirect vaccine effect-
iveness9,11 and vaccine safety,19 provided insights into vac-
cination coverage14,15 and facilitated cost-effectiveness
analyses using models for pneumococcal,24 rotavirus25 and
Hib vaccines,26 and thus directly influenced national and
regional policy.
Vaccine monitoring is conducted in clinics entirely by
CDOH staff. The KWTRP provides the design, training
and data collation, cleaning and analysis. This integration
with the health ministry personnel is another strength of
KIVMS that has been shaped significantly by more than a
decade of collaboration. This has proved essential both for
the smooth running of the programme and for the effective
use of results.
The KEMRI Scientific and Ethics Review Unit (SERU)
approved the creation of KiVMS as part of the KWTRP.
Importantly, all community-based research at the KWTRP
are part of an integrated system of community engagement
using a wide range of channels including community repre-
sentative groups and open public meetings to ensure that
the research conducted under KiVMS is locally relevant.
As expected of a resource-poor setting, there are chal-
lenges of logistics and infrastructure. The limited coverage
and instability of power supplies, along with inadequate
roads and mobile phone networks, present tremendous
challenges. As the project did not have capacity for elec-
tronic data capture during outreach services (where health-
care workers travel intermittently to numerous alternative
delivery points, e.g. schools), back-up paper systems were
deployed. Supplementary immunization activities (e.g. for
measles and polio) are also conducted in KHDSS commun-
ities from time to time. However, the present infrastructure
of KiVMS only allows for the recording of routinely de-
livered vaccinations.
In KiVMS, it is critical to identify individuals accurately
from the population register and link them to events such
as vaccination or hospital admission. Identification is gen-
erally easier at vaccine clinics than hospitals because moth-
ers and data clerks know the local area in detail and
geographical residence is a key identity criterion. However,
vaccine clinics are very busy environments and personal
identity (ID) matching is still slow and occasionally in-
accurate. An incident record is opened when an ID mis-
match occurs, which is resolved by data supervisors and
managers of the vaccine registry and KHDSS at the
KWTRP. Fingerprinting technology solutions were con-
sidered but would not work for our primary target popula-
tion–young infants–as their fingerprint patterns are not
reliably distinguished at this age.
Although KHDSS detects in- and out-migrations in its
study area, the data capture in local clinics cannot record
vaccinations received by migrants if they had received all
of their vaccines before moving into the area and do not
visit the vaccine clinics nor experience hospitalization at
KCH. In addition, migration itself may be a risk factor for
poor uptake.27,28 Consequently, data for migrants are less
complete and there is a risk of misclassification. To capture
these data as far as it is practically possible, we instituted
vaccine-card surveillance for KHDSS immigrants aged < 5
years, which is effectively a small population sample, dur-
ing re-enumeration rounds. This will improve complete-
ness of data for this small but often at-risk group. In Table
2, we show the merits of an electronic vaccine registry
compared with use of HDSS enumeration rounds for rou-
tine collection of all vaccine data.
KHDSS, the largest surveillance of its kind in tropical
Africa, is suitable for the study of vaccine impacts against
common diseases (e.g. invasive Hib and pneumococcal dis-
ease) but cannot provide the richness of detail, e.g. strain-
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specific or age-specific vaccine efficacy afforded by na-
tional surveillance systems. This limitation is most
apparent in the study of vaccine safety, as the levels of
severe AEFI for licensed vaccines are infrequent in epi-
demiological terms and cannot easily be associated
with vaccine in a population of this size. One solution to
this is to link several HDSS platforms together, within
country as we have done in Kenya, to examine PCV10
safety.19
Can I get hold of the data? Where can I find
out more?
Investigators with interest in datasets or collaborations can
contact Millicent Odhiambo [modhiambo@kemri-well-
come.org] and the KWTRP data governance committee
[dgc@kemri-wellcome.org] with a statement of request and
formal application for data transfer. In addition, they can
contact the principal investigator, Professor Anthony Scott
[ascott@kemri-wellcome.org] and/or co-investigator, Dr
Ifedayo Adetifa [IAdetifa@kemri-wellcome.org]. There is
more information on the KWTRP website [www.kemri-
wellcome.org].
Table 2. Advantages and disadvantages of the use of a clinic-based electronic vaccine monitoring system compared with vac-
cine card verification during enumerations rounds in a health and demographic surveillance system
Vaccine Registry Vaccine card survey at enumeration rounds
1. Allows for real-time monitoring vaccine coverage data 1. It cannot provide real-time vaccine coverage data
2. Facilitates rapid intervention/reaction to improve coverage
and/or correct immediate problems
2. Produces data too late for directing interventions for problem
solving or to improve coverage
3. More difficult to initiate but relatively easy to maintain 3. Convenient and relatively easier to set up
4. Not dependent on good record keeping and entries at vaccine
clinic, but electronic platform helps improve record keeping
4. Dependent on good record keeping and entries at vaccine
clinics
5. Response rate is not dependent on card retention, data are
obtained at real time in vaccine clinics
5. Response rate is dependent on card retention in population
6. Risk of missing data in migrants, especially older children 6. May miss migrants but more likely to reach them with
repeated cycles of data collection
7. Facilitates linkages across all vaccine clinics and electronic
health records at referral hospital and for catchment
population
7. Not possible to link to morbidity and other registries in real
time
8. Provides more opportunities for updating vaccine records
especially when linked with hospital and other records
8. Typically stand-alone and does not provide other opportuni-
ties for updating individual vaccine records
9. Less risk of non-response error and missing data 9. Increased risk of non-response error
10. Can be used or linked to other modules for increasing vac-
cine coverage, e.g. reminders/recall
10. Cannot be linked or extended to serve other purposes such as
reminders/recall for vaccination
11. Has utility for tracking, for example bar-coded vaccine vials,
and for vaccine-associated adverse events surveillance for
assurance of vaccine safety
11. Contributes very little to surveillance of vaccine-associated
adverse events
12. Not dependent on presence of primary caregiver 12. Dependent on presence of card holder/primary caregiver
who is often not available
13. Requires more investment since it is population wide 13. Relatively cheaper when limited to a sample of the target
population, like migrants in this case
Profile in a nutshell
• The Kilifi Vaccine Monitoring Study (KiVMS) is
a long-term continuous cohort study set up to inves-
tigate effectiveness, impact, coverage, safety and
indirect vaccine effects by recruiting birth co-
horts and, where applicable, cohorts of older and
adults.
• It is based in the area covered by the Kilifi Health
and Demographic Surveillance System, Kilifi, Kenya,
and currently has records of 33 962 children in the
birth cohort database.
• A major strength of KiVMS is its unique integration
of a vaccine registry, a morbidity surveillance sys-
tem and the largest health and demographic surveil-
lance system (HDSS) in Africa.
• Requests for data and/or collaboration should be
sent to [dgc@kemri-wellcome.org and
MOdhiambo@kemri-wellcome.org]
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